Later, another study showed that a Parthenolide (PTL)-derived drug DMOCPTL directly bound to the GPX4 active site (selenocysteine 46), and led to GPX4 ubiquitination in triple-negative breast cancer cells (Ding et al., 2021). Here, GPX4 is linked to triple-negative breast carcinoma.